ClinicalTrials.Veeva

Menu

Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial (EPL)

N

National University Health System (NUHS)

Status

Unknown

Conditions

Gastric Cancer

Treatments

Procedure: Extensive Peritoneal Lavage

Study type

Interventional

Funder types

Other

Identifiers

NCT02140034
EPL Study
2013/00172 (Other Identifier)

Details and patient eligibility

About

This study is carried out to determine the merit and reliability of extensive intraoperative peritoneal lavage as a preventive strategy

Hypothesis: EPL significantly improve the overall survival of patients by reducing the risk of peritoneal recurrence

Full description

Gastric cancer is the second most common cause of cancer death worldwide. Surgery is the mainstay treatment for cure. Peritoneum is a common site of recurrence and the prognosis in patients with peritoneal recurrence is dismal. Hence, prevention is essential to patient's outcomes. In patients with serosal invasion, about half experience peritoneal recurrence within first 2 years after surgery, even after curative surgery. Peritoneal metastasis is caused by the implantation of free cancer cells in the peritoneal cavity exfoliated from the primary tumor before or during curative surgery. It is well known that cancer cells spillage could occur during surgery due to manipulation or even after lymph node dissection. If we can remove these free exfoliated cancer cells on the peritoneal lining, we may reduce the risk of tumor recurrence.

Recently, a study has demonstrated a dramatic reduction of peritoneal recurrence with extensive peritoneal lavage (EPL) in patients who underwent curative resection of gastric cancer. EPL was performed after the curative operation . The peritoneal cavity was washed with normal saline which is then followed by the complete aspiration of the fluid. This procedure was done 10 times using 1 liter of normal saline. The method was based on the 'limiting dilution theory' in which the method can dilute the number of free cancer cells to minimal hence reduce the risk of tumor implantation. In this study, among patients with microscopic peritoneal metastasis, peritoneal recurrence developed in 40% of patients with EPL and surgery, compared to 89.7% in patients with surgery alone. EPL carries minimal risk to patients. It is simple and inexpensive, and it is not time consuming. Hence, it may be an effective strategy for treatment of gastric cancer.

Enrollment

600 estimated patients

Sex

All

Ages

21 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who have T3 (subserosal) or T4 (serosal) disease based on CT scan and intra-operative inspection with any N staging and M0 gastric cancer.
  • Patients planned for open or laparoscopic gastrectomy.
  • Patients undergoing gastrectomy with curative intent.
  • Lower age limit of research subjects 21 years old and upper age limit of 80 years old.
  • Ability to provide informed consent

Exclusion criteria

  • Patients who undergo a palliative gastrectomy.
  • Patients who undergo a gastrectomy as emergency.
  • Vulnerable persons under age of 21.
  • Patients receiving neoadjuvant therapy.
  • Patients presented with life-threatening bleeding from tumour
  • ASA score of 4 & 5
  • Patients with another primary cancer within last 5 years
  • Patients with gross peritoneal and liver metastasis at surgery.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

600 participants in 2 patient groups

Study Arm: Extensive Peritoneal Lavage
Experimental group
Description:
The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
Treatment:
Procedure: Extensive Peritoneal Lavage
Control Arm: Standard Treatment
No Intervention group
Description:
The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.

Trial contacts and locations

1

Loading...

Central trial contact

Amy Tay, Nursing; Jimmy So, MBChB

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems